TX-LIGHTBEAM-HEALTH
9.8.2021 20:33:22 CEST | Business Wire | Press release
Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, is proud to announce their partnership with Ambry Genetics, a Konica Minolta Precision Medicine (KMPM) company. The partnership provides precision genetic testing data within the Lightbeam application to help organizations predict increased risk for common cancers and chronic conditions within patient populations.
According to the Centers for Disease Control and Prevention , 1.6 million people are diagnosed with cancer each year in the United States. The Ambry Genetics-Lightbeam partnership is expected to reduce this burden with tools for early detection and prevention by allowing providers to quickly identify, assess, and engage patients who meet specific risk factors. As the body of genetic evidence expands, so too will the value brought to mutual clients of Lightbeam and Ambry Genetics.
The CARE (Comprehensive, Assessment, Risk and Education) Program™ will integrate into the Lightbeam Platform, providing an additional clinical data stream for clients to enhance Lightbeam’s proprietary Ability-to-Impact (ATI) risk score. Genetic risk information is critical because it informs personalized patient care to include preventive surgeries, increased cancer screening, and in some cases, targeted therapies.
“At Lightbeam, part of our vision is to help organizations transform care delivery from being reactive to proactive,” said Pat Cline, CEO of Lightbeam. “We believe this partnership with Ambry Genetics will positively impact lives with its ability to indicate whether a person is high-risk for cancer or other diseases. In combination with our industry-leading analytics platform, Ambry’s genetic data further enhances how Lightbeam clients can improve quality, reduce costs, and positively impact outcomes for the populations they serve.”
“Today, only a fraction of individuals with a hereditary predisposition to disease are tested,” said Rob Guigley, Chief Commercial Officer, Ambry Genetics. “Our partnership with Lightbeam intends to bring greater access to the community and empower patients and providers to make informed preventative decisions that can improve health care and management. The potential impact of this relationship is significant for patients, providers, and payors.”
For more information on this innovative partnership, visit the Lightbeam Health booth , #2060 in the Sands Expo, at HIMSS21 in Las Vegas, Nevada, from August 9-13, 2021.
About AMBRY GENETICS ®
Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions.
About Lightbeam Health Solutions
Lightbeam Health Solutions delivers a revolutionary model for managing patient populations and associated risk. Lightbeam’s vision is to bring health data into the light through the use of analytics, and to provide the insight and capabilities healthcare clients need to ensure patients receive the right care at the right time. Lightbeam’s platform facilitates end-to-end population health management for ACOs, payers, provider groups, health systems, and other healthcare organizations aspiring to provide superior care at a lower cost. For more information, visit www.lightbeamhealth.com , and follow Lightbeam on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005688/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 09:00:00 CEST | Press release
At Microsoft’s Innovation Hub in Amsterdam, immersive technology is used to enable co-creation rather than one-way presentations. In the company’s Immersive Suite, customers, data experts, and technology specialists come together in a shared environment to address complex challenges more effectively. Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That all
LTM Launches AI 1000 to Develop the Next Generation of Forward Deployed Engineers12.6.2026 08:14:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced AI 1000, a strategic workforce transformation initiative anchored by a dedicated Center of Excellence (CoE). The program will develop a pool of 1,000+ AI-certified engineers, including Forward Deployed Engineers (FDEs), to help enterprises adopt, deploy, and scale AI. The launch comes amid a major shift in enterprise tech talent. The FDE — among the fastest-growing roles in the AI ecosystem — combines the technical knowledge of LLMs and domain SLMs with business understanding to turn ideas into quantifiable ROI accretive outcomes and to drive client adoption. AI 1000 is LTM’s structured response to this shift: it provides the training, platforms, and governed career frameworks to develop FDEs at scale. AI 1000 takes an end-to-end approach to talent development via a four-stage model: Identify, Enable, Deploy, and Govern. It starts by identifying high-potential engineers using a proprietary AI Readi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
